HORROR Y BRONCA
Mediante licitaciones armadas a medida de droguerías amigas, en un solo medicamento (Macitentan), el gobierno pagó $8 millones por unidad cuando su valor de mercado ronda los $400 mil.
Configurando una estafa histórica a personas con discapacidad.
Mediante licitaciones armadas a medida de droguerías amigas, en un solo medicamento (Macitentan), el gobierno pagó $8 millones por unidad cuando su valor de mercado ronda los $400 mil.
Configurando una estafa histórica a personas con discapacidad.
December 4, 2025 at 11:03 AM
HORROR Y BRONCA
Mediante licitaciones armadas a medida de droguerías amigas, en un solo medicamento (Macitentan), el gobierno pagó $8 millones por unidad cuando su valor de mercado ronda los $400 mil.
Configurando una estafa histórica a personas con discapacidad.
Mediante licitaciones armadas a medida de droguerías amigas, en un solo medicamento (Macitentan), el gobierno pagó $8 millones por unidad cuando su valor de mercado ronda los $400 mil.
Configurando una estafa histórica a personas con discapacidad.
Efficacy and Safety of Macitentan Across Pulmonary Hypertension Phenotypes: A Systematic Review and Meta-analysis https://www.medrxiv.org/content/10.64898/2026.09.22.26363639v1
September 23, 2026 at 5:55 PM
Efficacy and Safety of Macitentan Across Pulmonary Hypertension Phenotypes: A Systematic Review and Meta-analysis https://www.medrxiv.org/content/10.64898/2026.09.22.26363639v1
💊 HORROR Y BRONCA
Mediante licitaciones armadas a medida de droguerías amigas, en un solo medicamento (Macitentan), el gobierno pagó $8 millones por unidad cuando su valor de mercado ronda los $400 mil.
Configurando una estafa histórica a personas con discapacidad.
El 3% de la respostera...
Mediante licitaciones armadas a medida de droguerías amigas, en un solo medicamento (Macitentan), el gobierno pagó $8 millones por unidad cuando su valor de mercado ronda los $400 mil.
Configurando una estafa histórica a personas con discapacidad.
El 3% de la respostera...
TemplanzaSuramericana
💊 HORROR Y BRONCA
Mediante licitaciones armadas a medida de droguerías amigas, en un solo medicamento (Macitentan), el gobierno pagó $8 millones por unidad cuando su valor de mercado ronda los $400 mi...
t.me
December 3, 2025 at 11:16 PM
💊 HORROR Y BRONCA
Mediante licitaciones armadas a medida de droguerías amigas, en un solo medicamento (Macitentan), el gobierno pagó $8 millones por unidad cuando su valor de mercado ronda los $400 mil.
Configurando una estafa histórica a personas con discapacidad.
El 3% de la respostera...
Mediante licitaciones armadas a medida de droguerías amigas, en un solo medicamento (Macitentan), el gobierno pagó $8 millones por unidad cuando su valor de mercado ronda los $400 mil.
Configurando una estafa histórica a personas con discapacidad.
El 3% de la respostera...
MACITENTAN API | MANUFACTURER & BULK SUPPLIER FROM INDIA 🇮🇳
Looking for a reliable source of Macitentan API for pharmaceutical formulation and development requirements?
Swapnroop Drugs & Pharmaceuticals supplies quality-focused Macitentan Active Pharmaceutical Ingredient (API) to pharmaceutical
Looking for a reliable source of Macitentan API for pharmaceutical formulation and development requirements?
Swapnroop Drugs & Pharmaceuticals supplies quality-focused Macitentan Active Pharmaceutical Ingredient (API) to pharmaceutical
July 8, 2026 at 4:13 AM
MACITENTAN API | MANUFACTURER & BULK SUPPLIER FROM INDIA 🇮🇳
Looking for a reliable source of Macitentan API for pharmaceutical formulation and development requirements?
Swapnroop Drugs & Pharmaceuticals supplies quality-focused Macitentan Active Pharmaceutical Ingredient (API) to pharmaceutical
Looking for a reliable source of Macitentan API for pharmaceutical formulation and development requirements?
Swapnroop Drugs & Pharmaceuticals supplies quality-focused Macitentan Active Pharmaceutical Ingredient (API) to pharmaceutical
Long-term treatment with a single-tablet fixed-dose combination of #Macitentan and #Tadalafil is well tolerated and maintains efficacy over 2 years in patients with pulmonary arterial hypertension (#PAH).
Read more: https://bit.ly/3NJTUWA
#RareDisease #MedSky #PulmonaryArterialHypertension
Read more: https://bit.ly/3NJTUWA
#RareDisease #MedSky #PulmonaryArterialHypertension
Macitentan and Tadalafil Combination Shows Sustained Efficacy in PAH
In a recent study, long-term combination therapy with macitentan and tadalafil demonstrated favorable tolerability and sustained efficacy in patients with PAH.
bit.ly
March 27, 2026 at 10:13 PM
Long-term treatment with a single-tablet fixed-dose combination of #Macitentan and #Tadalafil is well tolerated and maintains efficacy over 2 years in patients with pulmonary arterial hypertension (#PAH).
Read more: https://bit.ly/3NJTUWA
#RareDisease #MedSky #PulmonaryArterialHypertension
Read more: https://bit.ly/3NJTUWA
#RareDisease #MedSky #PulmonaryArterialHypertension
💉 Treprostinil s.c. 60 ng/kg/min
💊 Macitentan 10 mg
💊 Tadalafil 40 mg
In this case, triple therapy not only lowers pulmonary pressures but also lets the RV work more efficiently — restoring RV-arterial coupling and reducing energetic strain.
💊 Macitentan 10 mg
💊 Tadalafil 40 mg
In this case, triple therapy not only lowers pulmonary pressures but also lets the RV work more efficiently — restoring RV-arterial coupling and reducing energetic strain.
September 15, 2025 at 9:39 PM
💉 Treprostinil s.c. 60 ng/kg/min
💊 Macitentan 10 mg
💊 Tadalafil 40 mg
In this case, triple therapy not only lowers pulmonary pressures but also lets the RV work more efficiently — restoring RV-arterial coupling and reducing energetic strain.
💊 Macitentan 10 mg
💊 Tadalafil 40 mg
In this case, triple therapy not only lowers pulmonary pressures but also lets the RV work more efficiently — restoring RV-arterial coupling and reducing energetic strain.
Macitentan Market Trends | Industry Analysis & Insights 2035 | WiseGuyReports www.wiseguyreports.com/reports/maci...
Macitentan Market Trends | Industry Analysis & Insights 2035
The Macitentan Market is expected to grow from 776.9 USD Million in 2025 to 1,200 USD Million by 2035. The Macitentan Market CAGR (growth rate) is expected to be around 4.4% | Wiseguy Reports
www.wiseguyreports.com
August 10, 2026 at 11:02 AM
Macitentan Market Trends | Industry Analysis & Insights 2035 | WiseGuyReports www.wiseguyreports.com/reports/maci...
Macitentan Market Trends | Industry Analysis & Insights 2035 | WiseGuyReports www.wiseguyreports.com/reports/maci...
Macitentan Market Trends | Industry Analysis & Insights 2035
The Macitentan Market is expected to grow from 776.9 USD Million in 2025 to 1,200 USD Million by 2035. The Macitentan Market CAGR (growth rate) is expected to be around 4.4% | Wiseguy Reports
www.wiseguyreports.com
August 5, 2026 at 10:58 AM
Macitentan Market Trends | Industry Analysis & Insights 2035 | WiseGuyReports www.wiseguyreports.com/reports/maci...
The #FDA recently eliminated the fetal toxicity risk-mitigation requirement for three #PH medications.
The Risk Evaluation and Mitigation Strategies requirement has been removed for ambrisentan, macitentan and the macitentan-tadalafil combination tablet.
Learn more: buff.ly/uK8yzdT
The Risk Evaluation and Mitigation Strategies requirement has been removed for ambrisentan, macitentan and the macitentan-tadalafil combination tablet.
Learn more: buff.ly/uK8yzdT
June 11, 2025 at 2:05 PM
The #FDA recently eliminated the fetal toxicity risk-mitigation requirement for three #PH medications.
The Risk Evaluation and Mitigation Strategies requirement has been removed for ambrisentan, macitentan and the macitentan-tadalafil combination tablet.
Learn more: buff.ly/uK8yzdT
The Risk Evaluation and Mitigation Strategies requirement has been removed for ambrisentan, macitentan and the macitentan-tadalafil combination tablet.
Learn more: buff.ly/uK8yzdT
Pulmonary arterial hypertension, it was for the meds ambrisentan and macitentan.
July 15, 2025 at 1:44 PM
Pulmonary arterial hypertension, it was for the meds ambrisentan and macitentan.
Open Access UCL Research: Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis DUAL-1 and DUAL-2 Randomized Clinical Trials
discovery.ucl.ac.uk/id/eprint/10...
discovery.ucl.ac.uk/id/eprint/10...
February 16, 2026 at 3:06 PM
Open Access UCL Research: Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis DUAL-1 and DUAL-2 Randomized Clinical Trials
discovery.ucl.ac.uk/id/eprint/10...
discovery.ucl.ac.uk/id/eprint/10...
Macitentan in Children with Pulmonary Arterial Hypertension: A Multicenter Experience link.springer.com/article/10.1... #hvhebron #cardioped
Macitentan in Children with Pulmonary Arterial Hypertension: A Multicenter Experience - Pediatric Cardiology
Macitentan seems to improve outcomes in patients with pulmonary arterial hypertension (PAH). Nevertheless, safety and efficacy in pediatric patients is still to be determined. Multi-center, observatio...
link.springer.com
July 7, 2025 at 11:34 AM
Macitentan in Children with Pulmonary Arterial Hypertension: A Multicenter Experience link.springer.com/article/10.1... #hvhebron #cardioped
PUBMED - Macitentan in the Treatment of Digital Ulcers in Patients with Systemic Rheumatic Autoimmune Diseases: A National Multicenter Study of 42 Patients pubmed.ncbi.nlm.nih.gov/41226942/ #produccionhuil #AnaSalomeParejaMartinez
Macitentan in the Treatment of Digital Ulcers in Patients with Systemic Rheumatic Autoimmune Diseases: A National Multicenter Study of 42 Patients - PubMed
<span><b>Objective:</b> To evaluate the real-world safety and efficacy of macitentan (MACI) in patients with systemic autoimmune rheumatic diseases (SARDs) and refractory digital ulcers (DUs).…
pubmed.ncbi.nlm.nih.gov
November 21, 2025 at 8:00 AM
PUBMED - Macitentan in the Treatment of Digital Ulcers in Patients with Systemic Rheumatic Autoimmune Diseases: A National Multicenter Study of 42 Patients pubmed.ncbi.nlm.nih.gov/41226942/ #produccionhuil #AnaSalomeParejaMartinez
A new observational study using INSPECTIO supports the effectiveness of guideline-directed therapy and regular risk assessment to optimize treatment strategies in Pulmonary Arterial Hypertension.
#PAH #ClinicalResearch #INSPECTIO #ObservationalStudy #Macitentan #Selexipag
doi.org/10.1016/j.vp...
#PAH #ClinicalResearch #INSPECTIO #ObservationalStudy #Macitentan #Selexipag
doi.org/10.1016/j.vp...
February 4, 2026 at 2:23 AM
A new observational study using INSPECTIO supports the effectiveness of guideline-directed therapy and regular risk assessment to optimize treatment strategies in Pulmonary Arterial Hypertension.
#PAH #ClinicalResearch #INSPECTIO #ObservationalStudy #Macitentan #Selexipag
doi.org/10.1016/j.vp...
#PAH #ClinicalResearch #INSPECTIO #ObservationalStudy #Macitentan #Selexipag
doi.org/10.1016/j.vp...
New insights on CTD-associated pulmonary arterial hypertension (CTD-PAH): an immune-driven, more aggressive form of PAH with worse survival than idiopathic PAH. Early combo therapy, close monitoring, and drugs like macitentan & selexipag show promise. #PAH #CTD #PulmonaryHypertension
August 29, 2025 at 7:27 AM
New insights on CTD-associated pulmonary arterial hypertension (CTD-PAH): an immune-driven, more aggressive form of PAH with worse survival than idiopathic PAH. Early combo therapy, close monitoring, and drugs like macitentan & selexipag show promise. #PAH #CTD #PulmonaryHypertension
New research in Pulmonary Circulation 🫁
Pregnancy Outcomes Following Macitentan or Bosentan Exposure Before or During Pregnancy: Review of Cases Reported to the Manufacturer's Global Safety Database
📆 20 Mar 2026
🔢 16(1), e70286
➡️ Read the article: onlinelibrary.wiley.com/doi/10.1002/...
Pregnancy Outcomes Following Macitentan or Bosentan Exposure Before or During Pregnancy: Review of Cases Reported to the Manufacturer's Global Safety Database
📆 20 Mar 2026
🔢 16(1), e70286
➡️ Read the article: onlinelibrary.wiley.com/doi/10.1002/...
April 2, 2026 at 9:57 AM
New research in Pulmonary Circulation 🫁
Pregnancy Outcomes Following Macitentan or Bosentan Exposure Before or During Pregnancy: Review of Cases Reported to the Manufacturer's Global Safety Database
📆 20 Mar 2026
🔢 16(1), e70286
➡️ Read the article: onlinelibrary.wiley.com/doi/10.1002/...
Pregnancy Outcomes Following Macitentan or Bosentan Exposure Before or During Pregnancy: Review of Cases Reported to the Manufacturer's Global Safety Database
📆 20 Mar 2026
🔢 16(1), e70286
➡️ Read the article: onlinelibrary.wiley.com/doi/10.1002/...
【エンドセリン拮抗薬は肺血管疾患合併HFmr/pEFの NT-proBNPを改善せず：RCT/ Circ HF】
・全世界142例ランダム化、24週観察。
・KCCQも改善せず。
・早期中止。
x.gd/44X6L
・全世界142例ランダム化、24週観察。
・KCCQも改善せず。
・早期中止。
x.gd/44X6L
Macitentan for Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Pulmonary Vascular Disease: Results of the SERENADE Randomized Clinical Trial and Open-Label Extension Study | Circu...
BACKGROUND: Despite favorable hemodynamic and neurohormonal effects, endothelin receptor antagonists
have not improved outcomes in patients with heart failure (HF), possibly because they
cause fluid r...
x.gd
March 13, 2025 at 2:15 AM
【エンドセリン拮抗薬は肺血管疾患合併HFmr/pEFの NT-proBNPを改善せず：RCT/ Circ HF】
・全世界142例ランダム化、24週観察。
・KCCQも改善せず。
・早期中止。
x.gd/44X6L
・全世界142例ランダム化、24週観察。
・KCCQも改善せず。
・早期中止。
x.gd/44X6L